ArQule Inc. (ARQL)
-NasdaqGM | Prev Close: | 2.36 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 4.67 |
|---|
| Beta: | 1.18 |
|---|
| Next Earnings Date: | 1-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.98 - 6.98 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 317,145 |
|---|
| Market Cap: | 147.79M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARQULE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Mon, 3 Jun)
- Phase 2 Study Results for Tivantinib in Combination with Cetuximab and Irinotecan for Colorectal Cancer Presented at ASCO 2013Business Wire(Sun, 2 Jun)
- ArQule, Inc. to Present at Jefferies 2013 Global Healthcare ConferenceBusiness Wire(Thu, 30 May)
- ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statements and ExhibitsEDGAR Online(Thu, 23 May)
- ARQULE INC FinancialsEDGAR Online Financials(Wed, 15 May)
- Earnings Volatility Drives These Healthcare Stocks in a New Directionat Wall St. Cheat Sheet(Mon, 13 May)
- Narrower-than-Expected Loss at ArQuleZacks(Fri, 10 May)
- ArQule Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, 9 May)
- ArQule Earnings: Everything You Must Know Nowat Wall St. Cheat Sheet(Wed, 8 May)
- Q1 2013 ArQule, Inc. Earnings Release - 07:00 am ETCCBN(Wed, 8 May)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 4.40 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.45 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.12 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -1.05 |
|---|
Business Summary
ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes.
View More